US equities |
SPCX $167.58 ▲+5.42% NVDA $236.13 ▲+0.93% MU $1,065.24 ▼-0.90% TSLA $378.11 ▲+2.03% MSFT $526.03 ▲+1.64% SNDK $1,710.40 ▼-0.56% INTC $117.27 ▼-1.72% META $743.94 ▲+2.18%
FinancialContent

Articles published by Corcept Therapeutics Incorporated

< Previous 1 2 Next >
News headline image
Corcept Announces Planned Leadership Transition
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
News headline image
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
< Previous 1 2 Next >